Unlike medical devices or drugs, AI software changes. Rather than issuing a one-time approval, FDA wants to monitor artificial intelligence products over time, something it's never done proactively.
A new report by the Government Accountability Office highlights the FDA's need for more power in regulating AI performance data and setting guardrails, but Congressional deliberation on AI regulation is still in its early stages.
[
add
]
[
|
|
...
]